

Vemlidy® Registration In The Developing World

Approved

1. Argentina	December 2017	5. Mongolia	June 2017
2. El Salvador	May 2018	6. Thailand	August 2018
3. Guatemala	June 2018	7. Uganda	April 2018
4. Mexico	December 2017	8. Uzbekistan	December 2017

Filed

1. Bolivia	June 2017	11. Kenya	March 2018	21. Rwanda	October 2017
2. Brazil	December 2017	12. Kyrgyzstan	July 2017	22. South Africa	October 2017
3. Chile	June 2017	13. Morocco	April 2018	23. Tanzania	October 2017
4. Colombia	September 2017	14. Mozambique	August 2018	24. Uruguay	July 2017
5. Costa Rica	September 2018	15. Nigeria	July 2017	25. Vietnam	January 2018
6. Dominican Republic	August 2018	16. Pakistan	July 2017	26. Zambia	September 2017
7. Ethiopia	January 2018	17. Panama	July 2017		
8. Ghana	September 2017	18. Paraguay	July 2017		
9. India	October 2017	19. Peru	July 2017		
10. Indonesia	May 2018	20. Philippines	May 2017		

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Vemlidy® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.